RT info:eu-repo/semantics/article
T1 Convalescent plasma therapy, therapeutic formulations of repurposed drugs in 20th century epidemics against COVID-19: A systematic review
A1 Fernández Lázaro, Diego
A1 Domínguez Ortega, Carlos
A1 Sánchez Serrano, Nerea
A1 Beddar Chaib, Fahd
A1 Jerves Donoso, David
A1 Jiménez Callejo, Elena
A1 Rodríguez García, Saray
K1 SARS-CoV-2
K1 COVID-19
K1 Convalescent plasma
K1 Plasma treatment
K1 Plasma
K1 Immunology
K1 Viral load
K1 Virology
K1 Virus
K1 Biomarkers
K1 Mortality
K1 Mortalidad
K1 Public Health
K1 2412 Inmunología
K1 2420 Virología
K1 3212 Salud Publica
K1 32 Ciencias Médicas
AB Coronavirus 2019 disease (COVID-19) represents one of the largest pandemics the world has faced, and it is producing a global health crisis. To date, the availability of drugs to treat COVID-19 infections remains limited to supportive care although therapeutic options are being explored. Some of them are old strategies for treating infectious diseases. convalescent plasma (CP) therapy has been used successfully in other viral outbreaks in the 20th century. In this study, we systematically evaluated the effect and safety of CP therapy on hospitalized COVID-19 patients. A structured search was conducted following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines using Medline (PubMed), SciELO, Cochrane Library Plus, Web of Science, and Scopus. The search included articles published up to January 2022 and was restricted to English- and Spanish-language publications. As such, investigators identified six randomized controlled trials that met the search criteria. The results determined that in hospitalized COVID-19 patients the administration of CP therapy with a volume between 200–500 mL and a single transfusion performed in 1–2 h, compared to the control group, decreased viral load, symptomatology, the period of infection, and mortality, without serious adverse effects. CP did influence clinical outcomes and may be a possible treatment option, although further studies will be necessary.
PB MDPI
SN 1999-4923
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/62704
UL https://uvadoc.uva.es/handle/10324/62704
LA eng
NO Pharmaceutics, 2022, Vol. 14, Nº. 5, 1020
NO Producción Científica
DS UVaDOC
RD 24-nov-2024